Details

Autor(en) / Beteiligte

• Español-Rego, Marta
• Fernández-Martos, Carlos
• Elez, Elena
• Foguet, Carles
• Pedrosa, Leire
• Rodríguez, Nuria
• Ruiz-Casado, Ana
• Pineda, Estela
• Cid, Joan
• Cabezón, Raquel
• Oliveres, Helena
• Lozano, Miquel
• Ginés, Angels
• García-Criado, Angeles
• Ayuso, Juan Ramon
• Pagés, Mario
• Cuatrecasas, Miriam
• Torres, Ferràn
• Thomson, Timothy
• Cascante, Marta
• Benítez-Ribas, Daniel
• Maurel, Joan

Titel

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study

Ist Teil von

• Cancer Immunology, Immunotherapy, 2023-04, Vol.72 (4), p.827-840

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects. Methods This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage. Results A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1–5.3 months] and overall survival was 12.2 months [3.2–23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways. Conclusions The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities.